Information Provided By:
Fly News Breaks for January 31, 2018
IMGN
Jan 31, 2018 | 07:09 EDT
H.C. Wainwright analyst Debjit Chattopadhyay started ImmunoGen with a Buy rating and $18 price target. The analyst believes ADC's, a multi-component system involving a targeting antibody linked to cytotoxic agents, have a "significant and hitherto underappreciated role to play in the war against cancer." He believes ImmunoGen has a differentiated ADC platform.
News For IMGN From the Last 2 Days
There are no results for your query IMGN